Carcinogenesis Advance Access published online on July 19, 2006
Carcinogenesis, doi:10.1093/carcin/bgl069
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 National Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Guo Xue Xian No. 37, Chengdu, Sichuan, The People's Republic of China
* To whom correspondence should be addressed. Mesenchymal stem cells (MSCs) were adenovirally engineered to secrete interleukin-12 (AdIL-12-MSCs) and evaluated for their anticarcinogenesis efficacy against three kind unestablished tumor models including B16 melanoma, LLC Lewis lung cancer and HCC hepatoma. Injection of AdIL-12-MSCs into protected mice prior to tumor inoculation resulted in all of twelve mice in B16 preventive groups, ten out of twelve in LLC lung cancer model and eleven out of the twelve mice in HCC hepatoma model did not develope tumors, whereas the control groups pre-receiving PBS were validated 100% of carcinogenesis; the tumor formation rates in free AdIL-12 and vacant MSC groups were unveiled between about 83% and 100% even with plentiful angiogenesis and newborn lymphatic vessels as well as distant metastases. As a novel approach, AdIL-12-MSC has revealed expectant preventive effects on carcinogenesis (P < 0.01) with low-toxic, broad-spectrum and long-range superiorities. In conclusion, our data indicated that AdIL-12-MSC possesses the potential for tropism to preclinical tumor lesions and deprives surviving or hibernating tumor cells which have escaped from conventional treatments of revival and recurrence.
Received October 4, 2005
Revised March 4, 2006
Accepted April 21, 2006
MOLECULAR EPIDEMIOLOGY AND CANCER PREVENTION
Prophylaxis against carcinogenesis in three kind unestablished tumor models via IL12-gene-engineered MSCs
Rui Wang 1 *, Xian-cheng Chen 2 *, Xia Zhao 3, Yu-quan Wei 1 *, Min Hu 1, Guo-qing Wang 1, Xiao-wei Zhang 1, Ru Zhang 1, Lin Zhang 1, Bin Yao 1, Lian Wang 1, Yong-qian Jia 1, Ting-ting Zeng 1, Jin-liang Yang 1, Ling Tian 1, Bing Kan 1, Xiao-juan Lin 3, Song Lei 1, Hong-xin Deng 1, Yan-jun Wen 1, Yong-qiu Mao 1, and Jiong Li 1
2 National Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Guo Xue Xian No. 37, Chengdu, Sichuan, The People's Republic of China; Department of Gynecology and Obstetrics, Second West China Hospital, West China Medical School, Sichuan University, Chengdu, Sichuan, The People's Republic of China, 610041
3 Department of Gynecology and Obstetrics, Second West China Hospital, West China Medical School, Sichuan University, Chengdu, Sichuan, The People's Republic of China, 610041
Yu-quan Wei, E-mail: yuquawei{at}vip.sina.com; yuquawei@hotmail.com
Abstract
*Rui and Chen contributed equally to the work.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. R. Loebinger, A. Eddaoudi, D. Davies, and S. M. Janes Mesenchymal Stem Cell Delivery of TRAIL Can Eliminate Metastatic Cancer Cancer Res., May 15, 2009; 69(10): 4134 - 4142. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Loebinger, E. K. Sage, and S. M. Janes Mesenchymal Stem Cells as Vectors for Lung Disease Proceedings of the ATS, August 15, 2008; 5(6): 711 - 716. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Eliopoulos, M. Francois, M.-N. Boivin, D. Martineau, and J. Galipeau Neo-Organoid of Marrow Mesenchymal Stromal Cells Secreting Interleukin-12 for Breast Cancer Therapy Cancer Res., June 15, 2008; 68(12): 4810 - 4818. [Abstract] [Full Text] [PDF]
|
|